Amgen (AMGN) has been highlighted by Zacks as a compelling value stock, despite its Zacks Rank #3 (Hold) rating, due to an attractive 'B' Value Style Score and a forward P/E of 13.63. The biotechnology firm, which is managing competition for its mature products with growth from newer blockbusters, has seen positive analyst sentiment, evidenced by 12 upward revisions to its fiscal 2025 earnings estimates, raising the consensus to $21.11 per share. This combination of valuation, strategic product management, and analyst confidence positions AMGN as a noteworthy consideration for investors.
Amgen (AMGN) presents a notable value proposition despite its neutral Zacks #3 (Hold) rating, supported by strong underlying metrics. The company's 'B' grade for both its Value Style Score and overall VGM Score signals strength, which is quantitatively underscored by an attractive forward P/E ratio of 13.63. Fundamentally, Amgen is navigating a product lifecycle transition where declining sales from legacy drugs like Epogen and Enbrel, which face biosimilar competition, are being offset by growth from blockbuster products such as Prolia and Xgeva. The forward-looking sentiment from analysts is a significant positive catalyst; over the last 60 days, 12 analysts have revised their fiscal 2025 earnings estimates upwards, lifting the Zacks Consensus Estimate by $0.29 to $21.11 per share. This optimism is further supported by the company's historical performance, which includes an average positive earnings surprise of 11.8%, indicating a consistent ability to exceed market expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
